HKEX Stock Code: 01093
English
|
繁體
|
简体
Home
About Us
Products
News
Competence
Investor Relations
Contact Us
Corporate Profile
Corporate Information
Corporate Culture
Board of Directors
Corporate Governance
Products Overview
Finished Drugs
Bulk Drugs
Press Releases
Strategies
Quality
Research and Development
IR Overview
Financial Reports
CSR Reports
Announcements & Notices
Returns on Share Capital
Circulars
Presentations
Documents on Display
Shareholder Services
Notice(s) of Replacement
of Lost Share Certificates
Financial Calendar
Financial Summary
Environmental, Social and Governance (ESG) Policy
IR Contacts
Latest News
Sep
09
VOLUNTARY ANNOUNCEMENT - ROTIGOTINE LONG-ACTING INJECTION (SYH9087 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Sep
09
VOLUNTARY ANNOUNCEMENT - GOSERELIN SUSTAINED-RELEASE INJECTION (SYH9102 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN ...
Sep
08
VOLUNTARY ANNOUNCEMENT - INNOVATIVE CHEMICAL DRUG SYH2083 EYE DROPS OBTAIN CLINICAL TRIAL APPROVAL IN CHINA
/?php echo file_get_contents("https://www.irasia.com/cgi-local/adaptation/listco/hk/cspc/data.cgi?id=cspc&p=data&t=aclp&layout=home&n=3"); ?>
Financial Reports
2025 Annual Report
Highlight - 2026 Interim Results
Revenue
RMB18,594M, +40.1%
Reported profit attributable to shareholders of the Company
RMB6,094M, +139.2%
Underlying profit attributable to shareholders of the Company
RMB6,164M, +165.8%
Basic earnings per share (based on reported profit attributable to shareholders of the Company)
RMB53.45 cents, +139.8%
Key Products
Finished drugs
Bulk drugs
NBP (soft capsules)
NBP (injections)
Oulaining (capsules)
Oulaining (lyophilised powder for injections)
Enxi
Duomeisu
Jinyouli
Keaili
Shuluoke
Nuomoling
Weihong
Xinweihong
Xuanning
Encun
Qixiao
Linmeixin
Shuanglexin
Gubang
Gubangjia
Gaoshunsong
Debixin
Qimaite
Antibiotics
Vitamin C
Caffeine